XLRN News and Press, Acceleron Pharma Inc. From 08/08/21

Acceleron Pharma Inc. (XLRN) Q2 2021 Earnings Conference Call August 5, 2021 05:00 PM ET Company Participants Jamie Bernard - Associate Director of Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Jay Backstrom - Head of Research and Developm...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Acceleron Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Acceleron Pharma inc (NASDAQ: XLRN) Q2 2021 Earnings Call Aug 5, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Acceleron Pharma inc (XLRN) Q2 2021 Earnings Call Transcript

Acceleron Pharma (NASDAQ:XLRN): Q2 Non-GAAP EPS of -$0.81 beats by $0.04; GAAP EPS of -$1.05 misses by $0.15. Revenue of $27.94M (-29.8% Y/Y) misses by $2.98M. Press Release For further details see: Acceleron Pharma EPS beats by $0.04, misses on revenue

- Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day - - Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented...

- Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical com...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results. The webcast will be accessible under "Events & Presentations" in the Investors & ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) announce the first data from Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt) plus best supportive care in adult patients with non-transfusion dependent ((NTD)) beta thalassemia.Results demonstrated that 77.7% o...

Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the first data from the Phase 2 BEYOND study evaluating Reblozyl ® (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients...